Comments
Loading...
Cellectis (CLLS) Forecast
NewsEarningsCellectis (CLLS) OptionsGuidanceDividendsAnalyst RatingsInsider TradesShort InterestCellectis (NASDAQ:CLLS) Stock Quotes, Forecast and News Summary
Cellectis Stock (NASDAQ: CLLS) stock price, news, charts, stock research, profile.
Compare
EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
EPS worse than industry
FAQ
How do I buy Cellectis (CLLS) stock?
You can purchase shares of Cellectis (NASDAQ:CLLS) through any online brokerage.
Who are Cellectis (CLLS) competitors?
Other companies in Cellectis’s space includes: Zura Bio (NASDAQ:ZURA), Renovaro (NASDAQ:RENB), Innate Pharma (NASDAQ:IPHA), Aligos Therapeutics (NASDAQ:ALGS) and Adaptimmune Therapeutics (NASDAQ:ADAP).
What is the forecast, or price target, for Cellectis (CLLS) stock?
Cellectis has a consensus price target of $9.17.
What is the current price for Cellectis (CLLS)?
The stock price for Cellectis (NASDAQ: CLLS) is $1.57 last updated December 23, 2024 at 5:37 PM EST.
Does Cellectis (CLLS) pay a dividend?
There are no upcoming dividends for Cellectis.
When is Cellectis (NASDAQ:CLLS) reporting earnings?
Cellectis’s Q3 earnings are confirmed for Monday, November 4, 2024.
Is Cellectis (CLLS) going to split?
There is no upcoming split for Cellectis.
What sector and industry does Cellectis (CLLS) operate in?
Cellectis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.